{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging', 'paradigms. Survey of ophthalmology. 2010; 55(3): 215-26.', \"Noth D, Gebauer M, Muller B, et al. Graves' ophthalmopathy: natural history and treatment\", 'outcomes. Swiss medical weekly. 2001; 131(41-42): 603-9.', 'Perez A, Jansen-Chaparro S, Saigi I, et al. Glucocorticoid-induced hyperglycemia. Journal of', 'diabetes. 2014; 6(1): 9-20.', 'Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic', 'corticosteroids. Otolaryngologic clinics of North America. 2010; 43(4): 753-68.', 'Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant', \"expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like\", 'growth factor I receptor pathway. Journal of immunology (Baltimore, Md : 1950). 2003;', '170(12): 6348-54.', 'Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital', \"radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. The Journal\", 'of clinical endocrinology and metabolism. 2004; 89(1): 15-20.', \"Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. Jama. 1993; 269(4): 479-82.\", 'Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in', \"patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. The\", 'Journal of clinical endocrinology and metabolism. 2015; 100(2): 422-31.', 'Silkiss RZ, Reier A, Coleman M, et al. Rituximab for thyroid eye disease. Ophthalmic plastic', 'and reconstructive surgery. 2010; 26(5): 310-4.', 'Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic', 'target in autoimmune diseases? Pharmacological reviews. 2010; 62(2): 199-236.', \"Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan\", 'synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I', 'receptor. The Journal of clinical endocrinology and metabolism. 2004; 89(10): 5076-80.', 'Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy.', 'The New England journal of medicine. 2017; 376(18): 1748-61.', 'Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in', \"patients with Graves' orbitopathy. The Journal of clinical endocrinology and metabolism. 2015;\", '100(2): 432-41.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 113 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', \"Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy\", \"in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.\", 'The Journal of clinical endocrinology and metabolism. 2013; 98(4): 1443-9.', \"Terwee C, Wakelkamp I, Tan S, et al. Long-term effects of Graves' ophthalmopathy on health-\", 'related quality of life. European journal of endocrinology. 2002; 146(6): 751-7.', 'Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life', \"questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. The British journal of\", 'ophthalmology. 1998; 82(7): 773-9.', 'Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone', \"and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.\", 'Journal of immunology (Baltimore, Md : 1950). 2008; 181(6): 4397-405.', 'Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure:', 'comparison with insulin receptor suggests structural determinants that define functional', 'specificity. The EMBO journal. 1986; 5(10): 2503-12.', 'Weightman DR, Perros P, Sherif IH, et al. Autoantibodies to IGF-1 binding sites in thyroid', 'associated ophthalmopathy. Autoimmunity. 1993; 16(4): 251-7.', \"Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves'\", \"orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists,\", 'specialists and clinical researchers. European journal of endocrinology. 2006; 155(3): 387-9.', \"Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves'\", 'orbitopathy: efficacy and morbidity. The Journal of clinical endocrinology and metabolism.', '2011; 96(2): 320-32.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 114 of 117']\n\n###\n\n", "completion": "END"}